Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy

  • Authors:
    • Osamu Maeda
    • Ayumu Matsuoka
    • Kazuhiro Furukawa
    • Ryoji Miyahara
    • Yoshiki Hirooka
    • Yuichi Ando
  • View Affiliations

  • Published online on: May 10, 2019     https://doi.org/10.3892/mco.2019.1858
  • Pages: 91-98
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Resistance to anticancer drugs is a critical issue in cancer treatment. Alterations in gene expression and DNA methylation profiles that accompany the acquisition of drug resistance are associated with resistance mechanisms. To analyze chemotherapy‑associated alterations in gene expression and DNA methylation in gastric cancer cells obtained from ascites, ascitic fluids were collected from a patient with gastric cancer before chemotherapy with capecitabine and oxaliplatin (CapeOX), and after the disease had progressed. The fluids were cultured for 10 days, passaged into new flasks, and cultured for an additional 2 weeks. Normal cells, including white blood cells and mesothelial cells, were removed. The expression and DNA methylation profiles of 18,185 genes were analyzed using microarray, and compared between cells in ascitic fluids collected before and after the chemotherapy with CapeOX. In addition, fluorouracil‑ and oxaliplatin‑resistant AGS cells were established and analyzed. Pathways having genes with expression profiles altered by CapeOX included those associated with ‘signaling by G‑protein‑coupled receptor’ and the ‘immune system’. Genes that were commonly expressed at higher levels in CapeOX‑resistant ascitic cells, fluorouracil‑resistant AGS cells. and oxaliplatin‑resistant AGS cells compared with those in untreated cells included telomerase reverse transcriptase (TERT), apolipoprotein C1 (APOC1) and serine/threonine/tyrosine kinase 1 (STYK1), whereas genes commonly expressed at lower levels in the three drug‑resistant cell types compared with the untreated cells included defensin β4A (DEFB4A). A comparatively large number of genes exhibited altered methylation levels in drug‑resistant AGS cells compared with the CapeOX‑resistant cells. In addition, among the genes expressed at higher levels in decitabine‑treated AGS cells, the majority were expressed at higher levels in fluorouracil‑resistant AGS cells, and exhibited lower methylation levels. Taken together, the present study has demonstrated that comparing the expression profiles of gastric cancer cells obtained from ascitic fluids before and after chemotherapy with the expression profiles of drug‑resistant cultured cells is a useful method for analyzing the molecular mechanisms underlying chemotherapy resistance.

References

1 

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Tsuburaya A, Morita S, Kodera Y, Kobayashi M, Shitara K, Yamaguchi K, Yoshikawa T, Yoshida K, Yoshino S and Sakamoto J: A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer. 12:3072012. View Article : Google Scholar : PubMed/NCBI

3 

Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al: Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Maeda O, Ando T, Ohmiya N, Ishiguro K, Watanabe O, Miyahara R, Hibi Y, Nagai T, Yamada K and Goto H: Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol Rep. 31:1883–1890. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Maeda O, Ando T, Ishiguro K, Watanabe O, Miyahara R, Nakamura M, Funasaka K, Kazuhiro F, Ando Y and Goto H: Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer. Mol Clin Oncol. 2:1103–1106. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B. 57:289–300. 1995.

7 

Xu L, Corcoran RB, Welsh JW, Pennica D and Levine AJ: WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 14:585–595. 2000.PubMed/NCBI

8 

Kyo S, Takakura M, Fujiwara T and Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Yasui W, Oue N, Ito R, Kuraoka K and Nakayama H: Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 95:385–392. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Ko HL, Wang YS, Fong WL, Chi MS, Chi KH and Kao SJ: Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer. 5:500–508. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Liu L, Yu XZ, Li TS, Song LX, Chen PL, Suo TL, Li YH, Wang SD, Chen Y, Ren YM, et al: A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res. 64:3491–3499. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Kamino Y, Kurashige Y, Uehara O, Sato J, Nishimura M, Yoshida K, Arakawa T, Nagayasu H, Saitoh M and Abiko Y: HBD-2 is downregulated in oral carcinoma cells by DNA hypermethylation, and increased expression of hBD-2 by DNA demethylation and gene transfection inhibits cell proliferation and invasion. Oncol Rep. 32:462–468. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Li M, Zhang W, Zhang S, Wang C and Lin Y: PART1 expression is associated with poor prognosis and tumor recurrence in stage I–III non-small cell lung cancer. J Cancer. 8:1795–1800. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarnotta C, Zorzet S, Durigutto P, Botto M and Tedesco F: C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 7:103462016. View Article : Google Scholar : PubMed/NCBI

15 

Wen YG, Wang Q, Zhou CZ, Yan DW, Qiu GQ, Yang C, Tang HM and Peng ZH: Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol. 104:516–524. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, et al: Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res. 5:1046–1055. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Tan K, Kajino K, Momose S, Masaoka A, Sasahara K, Shiomi K, Izumi H, Abe M, Ohtsuji N, Wang T, et al: Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. Hum Pathol. 41:1330–1338. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Liu Y, An S, Ward R, Yang Y, Guo XX, Li W and Xu TR: G protein-coupled receptors as promising cancer targets. Cancer Lett. 376:226–239. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Maeda, O., Matsuoka, A., Furukawa, K., Miyahara, R., Hirooka, Y., & Ando, Y. (2019). Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy. Molecular and Clinical Oncology, 11, 91-98. https://doi.org/10.3892/mco.2019.1858
MLA
Maeda, O., Matsuoka, A., Furukawa, K., Miyahara, R., Hirooka, Y., Ando, Y."Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy". Molecular and Clinical Oncology 11.1 (2019): 91-98.
Chicago
Maeda, O., Matsuoka, A., Furukawa, K., Miyahara, R., Hirooka, Y., Ando, Y."Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy". Molecular and Clinical Oncology 11, no. 1 (2019): 91-98. https://doi.org/10.3892/mco.2019.1858